Zogenix to acquire Modis Therapeutics in £325m deal

This article was originally published here

The lead product candidate of Modis Therapeutics is MT1621, an investigational deoxynucleoside substrate enhancement therapy. Currently, MT1621 is in late-stage development for the treatment of Thymidine Kinase 2

The post Zogenix to acquire Modis Therapeutics in £325m deal appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply